IDO1 and inflammatory bowel disease: Consistent with a functional role for IDO1 expression in driving IBD-CRC development, mice treated with 1-L-MT had a significantly lower tumour number and tumour burden compared to mice treated with vehicle (Figs. 7B–D and S7A).